AOD9604 2AD 2mg*10vials

AOD9604 2AD (2mg x 10 vials) is a high-purity, optimized, freeze-dried lipolysis research peptide derived from a key truncated analog of human growth hormone (hGH) and modified with an upgraded 2AD molecule. Unlike traditional appetite-regulating metabolic peptides, AOD9604 2AD precisely targets lipid metabolism activation, exhibiting high targeted lipolysis efficiency, stable bioactivity, and low systemic irritation. The 2mg low-precision formulation is designed for fine-gradient dose screening, lipolysis mechanism research, long-term continuous metabolic intervention, and biosafety validation experiments, making it a core ingredient for preclinical lipid metabolism and adipose tissue remodeling research.

Product Function and Research Value

AOD9604 2AD possesses a unique targeted lipid metabolism regulatory effect without interfering with normal endocrine hormone balance. In laboratory studies, AOD9604 2AD primarily activates adipocyte metabolic pathways, accelerating the breakdown and oxidation of visceral and subcutaneous adipose tissue, and inhibiting adipocyte proliferation and lipid accumulation. Unlike GLP-1 peptides that rely on appetite suppression, AOD9604 2AD fundamentally regulates metabolism by activating lipid metabolism, supporting in-depth research on obesity, abnormal lipid deposition, adipose browning remodeling, and correction of lipid metabolism disorders. The optimized 2AD molecular structure enhances targeting specificity and anti-degradation stability, while the low 2mg dosage enables ultra-fine dose grouping and long-term repeated interventions, providing high-precision, low-interference, and reliable mechanistic data for cutting-edge lipid metabolism research.

Core Product Advantages

1. Optimized and Improved 2AD: The upgraded molecular structure improves lipid targeting affinity and in vivo stability, effectively reducing non-specific binding. Compared to ordinary AOD9604, it exhibits purer lipolytic activity and a more concentrated experimental phenotype.

2. Precise 2mg Low-Dose Dosage: The professional low-concentration design is suitable for fine-dose gradient experiments, long-term continuous modeling, and biosafety testing, avoiding experimental failures due to excessive dosage and enabling precise exploration of metabolic thresholds. 3. Unique Lipid Metabolism Mechanism: An independent lipolysis pathway, it does not affect appetite or normal hormone levels, achieving pure lipid metabolism intervention and filling a technological gap in targeted lipid regulation research.

4. Pharmaceutical-Grade Freeze-Drying Process: Aseptic vacuum freeze-drying locks in all peptide activity. Each batch undergoes rigorous HPLC purity testing and complete COA certification, exhibiting ultra-low impurities and excellent batch repeatability.

5. Standard 10-Vessel Packaging: 10 vials per box, integrated aseptic packaging, suitable for long-term laboratory storage, university lipid metabolism research projects, and professional bulk wholesale purchases.

AOD9604 2AD 2mg*10 vials This product is a high-purity, optimized, lysozyme-modified freeze-dried peptide, specifically for research use. It is a human growth hormone (hGH) cleavage analogue, employing a proprietary 2AD molecular modification upgrade process. Unlike traditional appetite-regulating metabolic peptides, AOD9604 2AD focuses on **targeted activation of lipid metabolism**, possessing strong lipolysis targeting, stable biological activity, and low body irritation. Its precise 2mg low-dose formulation is suitable for fine-gradient dose screening, lipid decomposition mechanism research, long-term continuous metabolic intervention, and biosafety verification experiments, making it a core raw material for preclinical lipid metabolism and adipose tissue remodeling research.

Core Uses and Research Value of Peptide Drugs

AOD9604 2AD possesses the ability to specifically target lipid metabolism regulation without interfering with the body's normal endocrine hormone balance, giving it unique research applications. It is primarily used to activate adipocyte metabolic pathways, accelerate the oxidative decomposition of visceral and subcutaneous fat, and inhibit adipocyte proliferation and abnormal lipid deposition. Unlike the appetite-suppressing mechanism of GLP-1 series peptide drugs, this product fundamentally activates the lipid metabolism cycle, achieving metabolic remodeling without suppressing appetite. It can provide strong support for cutting-edge research on the pathogenesis of obesity, abnormal lipid deposition, adipose browning remodeling, and the correction of lipid metabolism disorders. The upgraded 2AD molecular structure enhances targeting specificity and anti-degradation stability. Combined with the precise 2mg low-dose specification, it can effectively…